Skip navigation

Dr Simon Bridge

Senior Lecturer

Department: Applied Sciences

Simon Bridge Staffprofile Northumbriauniversity255

Simon is a viral immunologist who has worked in the field of virology and immunology since 1999 and gained considerable experience in academia, industry and the National Health Service. He trained in Immunology & Virology at Bristol University, Liverpool University, and the Liverpool School of Tropical Medicine. His PhD studies were supervised by Dr Tom Blanchard, the primary aim of his research work was to devise heterologous prime-boost-boost vaccines that would provide protection against HIV-1 by eliciting high titres of broadly reactive neutralising antibodies (Bridge et al., 2011a).

Simon returned to Newcastle University in 2006 for his postdoctoral research and worked in the laboratory of Professors Geoffrey Toms and Margaret Bassendine, and Dr Dermot Neely. His research focused on the association of hepatitis C virus (HCV) with very- and low-density lipoproteins (VLDL/LDL) in the blood of infected patient’s and to examine the metabolic factors, which influence this (Felmlee et al., 2010; Bridge et al., 2011b; Sheridan et al., 2012; Sheridan et al., 2014a, Bridge et al., 2015). This work culminated in a clinical trial investigating whether statins and n3 fatty acids reduced viral loads and the quantity of virus associated with LDL (Sheridan et al., 2014b).

In September 2015, Simon was appointed as a Senior Lecturer in Virology and Viral Immunology following a 3 year, Anniversary Research Fellow in the Faculty of Health & Life Sciences at Northumbria University. Simon maintains an active research interest in viral hepatitis and is particularly interested in the role of HCV in triggering atherosclerosis (Bridge et al., 2018). He is also interested in the role of the microbial communities in cardiovascular & pulmonary disease, inflammatory bowel disease and autoimmune liver disease.

Campus Address

Ellison building



Qualifications

Medicine PhD September 01 2003

Key Publications

  • Please visit the Pure Research Information Portal for further information
  • Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?, Bridge, S., Pagano, S., Jones, M., Foster, G., Neely, D., Vuilleumier, N., Bassendine, M. 8 Feb 2018, In: Hepatology International
  • Shigatoxin encoding Bacteriophage φ24B modulates bacterial metabolism to raise antimicrobial tolerance, Holt, G., Lodge, J., McCarthy, A., Graham, A., Young, G., Bridge, S., Brown, A., Veses-Garcia, M., Lanyon, C., Sails, A., Allison, H., Smith, D. 20 Jan 2017, In: Scientific Reports
  • Hepatitis C virus and atherosclerosis: A legacy after virologic cure?, Bassendine, M., Nielsen, S., Bridge, S., Felmlee, D., Sheridan, D., Packard, C., Neely, R. 11 Nov 2016, In: Clinics and Research in Hepatology and Gastroenterology
  • PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism, Bridge, S., Sheridan, D., Felmlee, D., Crossey, M., Fenwick, F., Lanyon, C., Dubuc, G., Seidah, N., Davignon, J., Thomas, H., Taylor-Robinson, S., Toms, G., Neely, R., Bassendine, M. Apr 2015, In: Journal of Hepatology
  • A metagenomic approach to characterize temperate bacteriophage populations from Cystic Fibrosis and non-Cystic Fibrosis bronchiectasis patients, Tariq, M., Everest, F., Cowley, L., de Soyza, A., Holt, G., Bridge, S., Perry, A., Perry, J., Bourke, S., Cummings, S., Lanyon, C., Barr, J., Smith, D. 18 Feb 2015, In: Frontiers in Microbiology
  • Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency, Sheridan, D., Bridge, S., Crossey, M., Felmlee, D., Thomas, H., Neely, R., Taylor-Robinson, S., Bassendine, M. Sep 2014, In: Metabolic Brain Disease
  • Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure., Macartney, M., Irish, D., Bridge, S., Garcia-Diaz, A., Booth, C., McCormick, A., Labbett, W., Smith, C., Velazquez, C., Tanwar, S., Trembling, P., Jacobs, M., Dusheiko, G., Rosenberg, W., Haque, T. May 2014, In: Antiviral Research
  • Lipids and HCV, Bassendine, M., Sheridan, D., Bridge, S., Felmlee, D., Neely, R. Jan 2013, In: Seminars in Immunopathology
  • Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination anti-viral therapy - a pilot randomised clinical trial, Sheridan, D., Bridge, S., Crossey, M., Felmlee, D., Fenwick, F., Thomas, H., Neely, R., Taylor-Robinson, S., Bassendine, M. 2013, In: Liver International
  • Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity, Sheridan, D., Bridge, S., Felmlee, D., Crossey, M., Thomas, H., Taylor-Robinson, S., Toms, G., Neely, R., Bassendine, M. 2012, In: Journal of Hepatology


+

Northumbria Open Days

Open Days are a great way for you to get a feel of the University, the city of Newcastle upon Tyne and the course(s) you are interested in.

Research at Northumbria
+

Research at Northumbria

Research is the life blood of a University and at Northumbria University we pride ourselves on research that makes a difference; research that has application and affects people's lives.

+

Order your prospectus

If you would like to know more about our courses, or life in general as a student at Northumbria, then we can help you.

Latest News and Features

More news
More events

Upcoming events

Back to top